GSK and Pfizer's RSV Vaccines Generate $12.6 Billion in Q3 2023 Amid Intensifying Market Competition

Nov 02, 2023 07:40 CST Updated 07:40

GSK

Pharmaceutical R&D Manufacturer

On November 1, GSK announced its third-quarter results, with revenue of £8.147 billion in the third quarter, a year-on-year increase of 10% (at constant exchange rates).

GSK's Most Outstanding Product This Quarter: RSV Vaccine Arexvy, with First-Quarter Revenue Reaching £709 Million ($880 Million). In Early May This Year, Arexvy Was the First to Receive FDA Approval for Marketing, Used to Prevent Lower Respiratory Tract Diseases (RSV-LRTD) Caused by RSV Infections in Adults Aged 60 and Above, Becoming the World’s First Launched RSV Vaccine.

Arexvy CurrentlyHas occupied60% of the U.S. retail market share, and 1.4 million American adults received this vaccine in the third quarter. Meanwhile,Arexvy alsoApproved and marketed in countries such as Europe, Canada, and Japan.

Results from a Phase III study showed,Arexvy's protective efficacy in preventing RSV infection in the 50-59 age group is non-inferior to its currently approved use in the 60 years and above population. GSK plans to submit an sBLA application to the FDA in the fourth quarter to seek approval for use in the 50-59 age group.

Pfizer's RSV vaccine Abrysvo was approved for marketing by the FDA at the end of May. According to Pfizer's recently announced third-quarter performance, the sales of this vaccine in the third quarter reached $375 million.August 21,AbrysvoNew IndicationFDA Approved, through active immunization of pregnant women, prevents RSV-related lower respiratory tract diseases in infants from birth to 6 months of age. This is the first FDA-approved protection for infants.Free from RSV-caused LRTD and severe LRTD from birth to 6 months of ageVaccination for Pregnant Women。

In addition to the two approved indications, Pfizer is targetingAbrysvoTwo new Phase III clinical trials have also been initiated to evaluate the vaccine forStrictPrevention of RSV Infection in High-Risk Adult Populations with Severe RSVDyeing,High-risk children for RSV aged above 2 and under 18Safety, ToleranceSex and immunogenicity.

The market competition between the two vaccines is very intense. From the current sales performance, GSK'sArexvy Takes the Lead. However, the future sales performance of the two products will depend on how well the two companies tap into their potential and the speed of their market promotion.In the near future, there will also be Moderna'smRNA-1345 joins the competition,The RSV vaccine market will also be divided among these three drugs.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank you for your companionship and we look forward to your feedback.

Scan the QR code to provide valuable suggestions